Parkinson Disease
Conditions
Keywords
Therapeutic education, Parkinson Disease, Socials representations
Brief summary
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.
Detailed description
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.
Interventions
OTHERTherapeutic education workshop
Workshop on Parkinson disease drug has several educative sequences (lasting 4hours). * A first round table is organized to know the needs and issues related to drug management of patients. * The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action. * The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly. * The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them. At the end, one patient explains its tips and tricks about its drug management
OTHERSpeaking Therapy
Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
Sponsors
University Hospital, Toulouse
France Parkinson Association
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
therapeutic education or speaking group
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria, * Patients who are already in therapeutic education program ETPARK, * Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug, * Patients with health insurance, * Patients who have signed a written informed consent form.
Exclusion criteria
* Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.), * Patients who has already done workshop on Parkinson disease drug (program ETPARK) * Patients already included in clinical trial during the study, * Patients who have severe psychiatric disorders or dopaminergic psychosis, * Patients with cognitive impairment, * Patients unable to complete the various scales used in the study, * Patients under juridical protection, * Women pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of Drug representation in Patients : BMQ | Three months | Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree". |
| Evolution of Drug representation in Patients : Verbal association | Three months | Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drug representation in caregivers : Verbal association | Day 1 | Drug representation through verbal association tasks. |
| Drug representation in caregivers : BMQ | Day 1 | Drug representation through the Believe about Medicines Questionnaire (BMQ). BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree". |
| Knowledge about the disease | three months | Evolution between Baseline and three months with a test created for the study. The test have 8 questions with two answers possible : True or False |
| Evolution in life quality : VAS | three months | Evolution in life quality evaluate with Visual Analog Scale (VAS), 0 being the worst quality of life and 10 the best quality of life he can have. Evolution between Baseline and three months |
| Evolution in life quality : PDQ-(39) | three months | Evolution in life quality evaluate with Parkinson Disease Quotation (PDQ)-39 with thirty-nine items coded from 1 " "always" to 5 "never". The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication. Evolution between Baseline and three months |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORChristine Brefel-Courbon, MD
Univeristy Hospital Toulouse
Outcome results
None listed